|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Centre de Recherche Pierre Fabre, Department of Cellular and Molecular Biology, Castres, France
Little experimental evidence has been reported for diverse signaling via 5-hydroxytryptamine (5-HT)1A receptors despite the fact that agonists seem to be more efficacious at dorsal raphe somatodendritic 5-HT1A autoreceptors than at postsynaptic 5-HT1A receptors. The present study investigated Ca2+ responses in Chinese hamster ovary (CHO)-K1 cells expressing a human 5-HT1A receptor by 5-HT, prototypical 5-HT1A agonists, N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methyl-6-; methylaminopyridin-2-yl)-methylaminomethyl]-piperidine (F 14679), and especially N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methylpyridin-2-yl)-; methylaminomethyl]piperidine (F 13640) as representative ligands of a new chemical class (methylamino-pyridine) that combines both high efficacy and selectivity for 5-HT1A receptors. 5-HT (pEC50 = 6.70 ± 0.02) induced a pertussis toxin-sensitive, transient high-magnitude Ca2+ response. High-magnitude Ca2+ responses (Emax, percentage versus 5-HT) were also found with F 13640 (107 ± 4), 5-carboxamidotryptamine (100 ± 3), and F 14679 (87 ± 3). In contrast, the prototypical 5-HT1A receptor agonists buspirone, ipsapirone, and 8-(hydroxy-2-(di-n-propylamino)tetralin, and also flesinoxan and eptapirone, were virtually inactive (
5). This atypical pattern of 5-HT1A receptor activation contrasts with the broad spectrum of the ligands' partial agonist properties as observed by measuring guanosine 5'-O-(3-[35 S]thio)triphosphate ([35S]GTP
S) binding responses with membranes of either CHO-K1 or C6-glial cells stably expressing a human 5-HT1A receptor. Remarkably, differences between ligands that seem small in the [35S]GTP
S binding assay translate into huge differences in the magnitude of Ca2+ responses. Therefore, some of these 5-HT1A ligands (i.e., F 13640) may in a selective way induce responses that may be not at all be achieved with other ligands (i.e., buspirone). In conclusion, the pharmacology of 5-HT1A receptor ligands seems to be codetermined by the effector pathway.
Address correspondence to: Dr. Petrus J. Pauwels, Centre d'Immunologie Pierre Fabre, 5, avenue Napoléon III-BP 497, F 74164 Saint-Julien-en-Genevois Cedex, France. E-mail: peter.pauwels{at}pierre-fabre.com
This article has been cited by other articles:
![]() |
D. Cussac, C. Palmier, F. Finana, L. DeVries, S. Tardif, C. Leger, S. Bernois, and P. Heusler Mutant 5-Hydroxytryptamine1A Receptor D116A Is a Receptor Activated Solely by Synthetic Ligands with a Rich Pharmacology J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 222 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Renner, K. Glebov, T. Lang, E. Papusheva, S. Balakrishnan, B. Keller, D. W. Richter, R. Jahn, and E. Ponimaskin Localization of the Mouse 5-Hydroxytryptamine1A Receptor in Lipid Microdomains Depends on Its Palmitoylation and Is Involved in Receptor-Mediated Signaling Mol. Pharmacol., September 1, 2007; 72(3): 502 - 513. [Abstract] [Full Text] [PDF] |
||||